Ranked #4,731 of 8,699 institutional investors
Rosalind Advisors, Inc.
Toronto, A6
$327M
US stock portfolio at live prices · today −$6.1M (−1.82%)
Live prices, last trade 10:25 AM ET
- Value at quarter end (Q3 2026)
- $309M
- Change from Q2 2026
- +$43.0M (+16.16%)
- Positions
- 31 · 7 new, 1 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: call options on $908K of stock, put options on $1.7M. $29.6M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesDCTH 19.4%XERS 13.2%FENC 12.6%VSTM 8.67%REPL 5.74%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| DCTH Delcath Systems, Inc. | 3,300,389 | $63.4M | 19.4% | Unchanged |
| XERS Xeris Biopharma Holdings, Inc. | 2,582,647 | $43.3M | 13.2% | Reduced −11% |
| FENC Fennec Pharmaceuticals Inc. | 3,188,001 | $41.2M | 12.6% | Unchanged |
| VSTM Verastem, Inc. | 4,236,509 | $28.3M | 8.67% | Added +6% |
| REPL Replimune Group, Inc. | 1,000,000 | $18.8M | 5.74% | New |
| SVRA Savara Inc. | 3,178,121 | $13.8M | 4.21% | Unchanged |
| VOR Vor Biopharma Inc. | 609,199 | $11.7M | 3.57% | Reduced −6% |
| XFOR X4 Pharmaceuticals, Inc. | 3,214,766 | $9.5M | 2.92% | Unchanged |
| PCVX Vaxcyte, Inc. | 149,361 | $8.6M | 2.63% | Reduced −25% |
| PEPG PepGen Inc. | 2,000,000 | $7.8M | 2.37% | Added +471% |
| AQST Aquestive Therapeutics, Inc. | 2,000,000 | $7.2M | 2.20% | Added +700% |
| TARA Protara Therapeutics, Inc. | 2,400,000 | $5.6M | 1.70% | New |
| PROF Profound Medical Corp. | 828,118 | $5.4M | 1.66% | Unchanged |
| BCRX BioCryst Pharmaceuticals, Inc. | 721,504 | $5.3M | 1.61% | Unchanged |
| RCKT Rocket Pharmaceuticals, Inc. | 2,200,000 | $4.6M | 1.42% | New |
| MYO Myomo, Inc. | 3,917,886 | $3.3M | 1.02% | Added +8% |
| TLPH Talphera, Inc. | 4,134,144 | $3.1M | 0.95% | Reduced −20% |
| OVID Ovid Therapeutics Inc. | 1,107,994 | $2.5M | 0.76% | Unchanged |
| NSPR InspireMD, Inc. | 3,905,743 | $2.4M | 0.73% | Unchanged |
| NRXS NeurAxis, Inc. | 548,123 | $2.4M | 0.72% | Added +8% |
| CGON CG Oncology, Inc. | 20,000 | $1.6M | 0.50% | New |
| ABVX ABIVAX Société Anonyme | 20,869 | $1.5M | 0.44% | Unchanged |
| AVIR Atea Pharmaceuticals, Inc. | 280,061 | $1.1M | 0.33% | Reduced −74% |
| BFRI Biofrontera Inc. | 1,789,288 | $1.1M | 0.32% | Added +40% |
| SPRB Spruce Biosciences, Inc. | 26,517 | $1.0M | 0.32% | Added +33% |
| FEMY Femasys Inc. | 759,213 | $954K | 0.29% | New |
| GRCE Grace Therapeutics, Inc. | 476,190 | $838K | 0.26% | New |
| KURA Kura Oncology, Inc. | 100,000 | $722K | 0.22% | Unchanged |
| ABOS Acumen Pharmaceuticals, Inc. | 1,100,000 | $198K | <0.1% | New |
| OKUR OnKure Therapeutics, Inc. | 67,506 | $185K | <0.1% | Reduced −55% |
| EYPT EyePoint, Inc. | 695,977 | $179K | <0.1% | Reduced −30% |
Sold out in Q3 2026
| Stock | Shares held at Q2 2026 | Worth today |
|---|---|---|
| CLDX Celldex Therapeutics, Inc. | 200,000 | $5.5M |